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The incidence of cutaneous melanoma has more than doubled over the last decades mak-
ing it one of the fastest rising cancers worldwide. Improved awareness and early detection
of malignant moles now permit earlier diagnosis aiming to decrease the likelihood of
recurrence. However, it is difficult to identify those patients initially diagnosed with local-
ized melanoma who subsequently develop metastatic disease. For this group, prognosis
remains poor and clinical outcomes are variable and challenging to predict. Considerable
efforts have focused on the search for novel prognostic tools, with numerous markers
evaluated in the circulation and in tumor lesions. The most reliable predictors of patient
outcome are the clinical and histological features of the primary tumor such as Breslow
thickness, ulceration status, and mitotic rate. Elevated serum levels of the enzyme lac-
tate dehydrogenase, likely to indicate active metastatic disease, are also routinely used to
monitor patients.The emergence of novel immune and checkpoint antibody treatments for
melanoma and increasing appreciation of key roles of the immune system in promoting
or halting cancer progression have focused attention to immunological biomarkers. Valida-
tion of the most promising of these may have clinical applications in assisting prognosis,
assessing endpoints in therapy, and monitoring responses during treatment.
Keywords: biomarkers, melanoma, humoral immunity, antibodies, cancer, prognosis, immune response,
inflammation
INTRODUCTION
The incidence rates of melanoma are rising constantly, faster than
for any other malignancy over the last two decades (1). Currently,
melanoma has an incidence rate of 12.4/100,000 and a mortal-
ity rate of 3/100,000 in the UK (worldwide ASR 3.1/10000 and
0.8/10000, respectively) (2). Higher reported incidence rates partly
reflect better surveillance and early diagnosis programs. Improve-
ments in early detection could help identify patients at earlier,
more curable disease stages, which may translate to enhanced
overall survival (OS) rates (3). Currently, however, the num-
ber of patients dying of the disease is significantly greater than
1.3% diagnosed with incurable metastatic disease at presentation,
implying a significant rate of disease progression in patients orig-
inally diagnosed with local disease (4–6). Treatment options for
these patients are limited despite recently approved and emerging
molecular targeted and immune therapies (7–9).
CLASSIFICATION AND STAGING
Cutaneous melanoma is classified into four types: (1) lentigoma-
ligna melanomas with a papular or nodular structure; (2) super-
ficial spreading (malignant) melanomas with large flat irregular
pigmented lesions that grow laterally before invading the dermis;
(3) nodular (malignant) melanomas with rapidly growing nod-
ules that tend to ulcerate and bleed; (4) acral lentigo (malignant)
melanomas mainly present at sites of friction, such as the sole,
palm, or under nails.
Similarly, staging of melanoma is determined according to
defined criteria (T: local extent of tumor; N: regional lymph-node
involvement; M: distance metastasis-classification, Table 1). These
parameters include the extent of dermal invasion (Breslow thick-
ness and Clark’s level); the presence of ulceration; the mitotic rate
of melanoma cells; and the presence of loco-regional or distant
metastases. Although more advanced disease stage correlates with
a worse prognosis, there have been reported cases of spontaneous
melanoma lesion regressions and remissions of systemic disease,
and this is perhaps attributed to immunological responses in these
patients (4).
LOCO-REGIONAL MANAGEMENT
Localized disease in melanoma is currently treated by surgical exci-
sion with a 0.5 cm surrounding margin for tumor in situ, 1 cm
margin for invasive melanoma of <2 mm Breslow thickness, and
2 cm margin for melanomas of≥2 mm thickness (10, 11). Routine
elective loco-regional lymphadenectomy has not been proven to
be superior to observation alone (12). However, sentinel lymph-
node biopsy has been suggested by several groups to be of benefit
for patients with stage IB disease or higher, allowing for more
accurate staging and therefore clearer information on prognosis
(12). Radiotherapy could be used for primary lesions only if unre-
sectable and for dissected lymph-node basins in patients at high
risk of recurrence (13, 14).
SYSTEMIC THERAPY
Conventional cytotoxic chemotherapy
Conventional cytotoxic drugs are largely ineffective in melanoma.
Dacarbazine (DTIC), until 2011 the only standard therapy,
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Table 1 |TNM classification.
Stage Primary tumor Lymph node Metastases
IA <1 mm, no ulceration, mitoses <1/mm2 (T1a)
IB <1 mm with ulceration or mitoses ≥1/mm2 (T1b)
1.01–2 mm, no ulceration (T2a)
IIA 1.01–2 mm, ulceration (T2b)
2.01–4 mm, no ulceration (T3a)
IIB 2.01–4 mm, ulceration (T3b)
>4 mm, no ulceration (T4a)
IIC >4 mm, ulceration (T4b)
IIIA Any thickness, no ulceration (T1–4a) 1 nodal micrometastases (N1a);
2–3 nodal micrometastases (N2a)
IIIB Any thickness, no ulceration (T1–4a) 1 nodal macrometastases (N1b);
2–3 nodal macrometastases (N2b)
Any thickness, ulceration (T1–4b) 1 nodal micrometastases (N1a);
2–3 nodal micrometastases (N2a)
Any thickness, no ulceration (T1–4a) In transit metastases/satellites,
no metastatic nodes (N2c)
IIIC T1–4b N1b–N2c
Any T stage 4+metastatic nodes, or matted nodes, or in
transit metastases/satellites with metastatic
nodes (N3)
IV Any T stage Any N stage Distant skin, subcutaneous, or nodal
metastases (M1a)
Any T stage Any N stage Lung metastases (M1b)
Any T stage Any N stage All other metastases or M1a/b sites with
raised LDH (M1c)
has a low objective response rate (<20%) in metastatic dis-
ease (7). Numerous other chemotherapeutic agents including
temozolomide, taxanes, fotemustine, and platin derivatives have
been unsuccessfully trialed as single agents, combinations, or in
conjunction with immune-modulators such as IFNα-2b or IL-2 at
the cost of significant toxicity (14, 15).
Molecular targeted therapies
An activating mutation in the BRAFV600 gene on the long arm
of chromosome 7 is found in approximately 50% of melanomas
(16, 17). This change results in the constitutive activation of BRAF
kinase, likely to promote RAS–RAF–MEK–ERK pathway-induced
melanoma cell survival and proliferation. Vemurafinib is a path-
way inhibitor drug that inhibits the mutated form of the BRAF
kinase. Although originally designed to block the V600E (glu-
tamate for valine) mutated form of BRAF, it can also inhibit
other mutant forms such as the V600K (lysine for valine) (7,
18–20). In stage IV disease, vemurafenib has been shown to
prolong progression-free survival (12.5 vs. 9.5 months) and OS
(13.6 vs. 9.7 months) in comparison to dacarbazine (DTIC) (21).
Vemurafenib, the first pathway inhibitor therapy approved for
melanoma in 2011, represented the first significant change in out-
look for stage IV disease in decades. However, following treatment,
the majority of treated patients develop secondary resistance to the
drug, thought to be associated with mechanisms overcoming the
blockade of BRAF kinase inhibitors and with alternative activa-
tion of the MAPK kinase pathway (22). Treatment has also been
linked to an enhanced risk of keratoacanthomas, squamous cell
carcinomas (SCC), and the development of new melanomas (23–
25) implying manipulation of other signaling cascades. Clinical
trials are ongoing for BRAF inhibitors in the adjuvant setting
and for combination therapies such as with BRAF and MEK
inhibitor drugs. Recently, two trials reported that the combination
of a BRAF inhibitor and a MEK inhibitor significantly improve
progression-free survival (26, 27). Standard clinical evaluation
now includes screening for the presence of the BRAF muta-
tion in excised high risk and metastatic melanoma deposits. This
test, now used for selecting patients to receive pathway inhibitor
treatment, may be considered as a co-diagnostic tool for this
treatment.
The identification of new mutations such as alternative BRAF,
NRAS, c-kit, GNA11, and GNAQ mutations has led to the devel-
opment of further kinase inhibitors and a number of these are
being assessed pre-clinically and in clinical trials.
Immune therapies
The efficacy of immune therapies such as pegylated IFNα-2b and
high dose IFNα-2b has been known for a number of years. These
adjuvant treatments have shown improved disease-free survival
(DFS), relapse-free survival (RFS) but only marginal improve-
ments for OS (14, 28, 29). Their cost and toxicity, however, mean
that their routine use is extremely limited. Likewise, high dose IL-2
was, until recently, the only effective therapy in stage IV disease,
capable in rare cases of inducing prolonged remission (15). High
Frontiers in Oncology | Cancer Epidemiology and Prevention January 2015 | Volume 4 | Article 383 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Karagiannis et al. Evaluating biomarkers in melanoma
toxicity confined treatment to a small subset of selected patients
and in specialist clinical centers.
Ipilimumab is an IgG1 monoclonal antibody that recognizes
the immune checkpoint cell surface molecule CTLA-4 on T cells.
The antibody blocks the binding of the immunomodulatory mol-
ecule CTLA-4 to CD80/CD86 on the surface of antigen-presenting
cells, preventing negative CTLA-4-mediated signals. This can
result in universal activation of T cells, including some capable
of specifically recognizing melanoma cells. Ipilimumab has shown
efficacy in several clinical trials in untreated and treated metastatic
patients in combination with a range of therapies such as pep-
tide vaccines and as a mono-therapy (8, 30, 31). Some long-term
responses are observed, albeit in a minority of patients and use
of this agent is associated with autoimmune-like toxicities, most
likely due to universal activation of CTLA-4-expressing T cells.
The agent was approved by regulatory authorities in metastatic
melanoma in 2011.
Based on the promise demonstrated by anti-CTLA-4 treat-
ment, antibodies against other immune regulatory proteins such
as PD-1, PD-L1, CD137, OX40, and CD40 are being investigated
(32, 33). Administration of the anti-PD-1 antibody nivolumab
demonstrated impressive objective responses in approximately
30% of individuals treated in a phase I trial (34). Combination
therapy with nivolumab and ipilimumab in a dosing study demon-
strated clinical safety and showed enhanced efficacy that appeared
to be superior compared to data published on either antibody
alone (35). Hamid et al. reported that the monoclonal antibody
lambrolizumab (anti-PD-1) can induce sustained tumor regres-
sion in patients that had refractory disease despite ipilimumab
treatment (36). Based on early clinical trial data, the anti-PD-
1 antibody pembrolizumab was approved for the treatment of
advanced melanoma in 2014 (37, 38).
The emergence of these new targeted and immune therapies,
their success in only subsets of patient groups, as well as the need
to assess patient benefit with combination treatments, all highlight
the need to develop a range of tools, not only for prognosis but also
to assist prediction and monitoring of treatment responses (39).
THE SEARCH FOR BIOMARKERS IN MELANOMA
The rapidly evolving clinical landscape of melanoma management
and therapy mandates the search for new candidate biomarkers.
Clinical trials traditionally rely on broad clinical groups and long-
term objective outcomes, for example, assessment of OS in patients
with previously treated stage IV melanoma. Patient stratification
is partly served by co-diagnostic tools, such as in the case of the
BRAF mutation test, which can help stratify patients who may
receive pathway inhibitor drugs; however, these co-diagnostics
do not always provide prognostic or predictive information. Bio-
markers could revolutionize the process of drug development and
those predictive of response could rationalize entry to trials for
those patients most likely to benefit (40). New reliable biomark-
ers are thus required for all stages of melanoma management to
assist with early detection, diagnosis, staging, prognosis as well as
prediction, and monitoring of treatment response.
Disease-relevant candidate markers for melanoma have
traditionally been derived from dissecting melanoma disease
pathways. A number of candidates have been studied in sera
and tumor specimens (Table 2) and some of these are dis-
cussed here. For this, a literature search using the search engine
“Pubmed” was conducted with the following keywords and
phrases: melanoma, malignant melanoma, metastatic melanoma,
biomarker, serum/tissue biomarker in melanoma, melanoma ther-
apy, melanoma immunotherapy, targeted therapy in melanoma,
S100 melanoma, lactate dehydrogenase (LDH) melanoma, Braf
melanoma, and diagnostic markers. All articles used in this review
were peer reviewed. Markers only reported in a single article (with
the exception of the immune inflammatory IL-8 and IgG4) were
excluded, and markers reported in the literature only before the
year 2000 were excluded.
SERUM BIOMARKERS FOR MELANOMA
Lactate dehydrogenase
The enzyme LDH is a clinical serological biomarker in melanoma.
It remains to date the strongest prognostic indicator found to be
elevated with tumor burden (67). LDH is mostly released upon cell
damage or death, with both phenomena indicating higher tumor
burden and disease progression. An increase in serum LDH is,
however, not specific to malignancy, but also occurs in many other
settings such as hemolysis, infection, infarction,and inflammation.
Therefore, the positive predictive value in melanoma is limited by
this false-positive rate (68). Recent studies have shown that LDH is
less sensitive in early stage disease, but has negative predictive value
for metastatic relapse (69–71). It is nonetheless at present a useful
and clinically available tool for indication of tumor progression in
patients at later disease stages and it is therefore incorporated in
the TNM classification (Table 1).
Tyrosinase
Tyrosinase is part of the biosynthesis process of melanin and
is constitutively expressed in melanocytes and melanoma cells.
Tyrosinase mRNA levels are detectable in the blood of melanoma
patients with advanced metastatic disease detected by nested RT-
PCR (42, 43). Initial evaluations revealed that tyrosinase is an
independent prognostic marker for tumor progression (42, 43,
72). Samija et al. demonstrated that tyrosine mRNA is associated
with a decrease in OS (44). However, high variability in the levels of
serum tyrosinase have been reported, most likely due to difficulties
in sample processing and the transient presence of metastasizing
tumor cells in the blood (43). Therefore, it is not surprising that
several studies could not confirm a significant prognostic utility
for tyrosinase (73). This includes a recent study that showed no
differences in tyrosinase serum levels when comparing patients to
healthy volunteers (74).
Vascular endothelial growth factor
Growth factors in combination with interleukins are major regula-
tors of inflammatory conditions in the tumor microenvironment.
Vascular endothelial growth factor (VEGF) is known to support
tumor-associated angiogenesis, and to contribute to inflammatory
conditions, which promote immunosuppression and redirection
of effective anti-tumoral immunity. Ugurel et al. reported that
VEGF was an independent prognostic marker for overall and
progression-free survival in their cohort (125 stage I–IV patients)
(50). Unfortunately, several subsequent studies could not con-
firm this finding. Although associations between VEGF and the
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Table 2 | Selected biomarker studies in melanoma.
Biomarker Study cohort Correlation Methodologya Reference
LDH 50 patients stage I–II and 61 patients stage IV
before and after treatment
Tumor stage; prognosis Photometric assay Egberts (41)
30946 patients stage I–III and 7972 stage IV Survival rate Meta-analysis Balch (4)
Tyrosine 200 patients stage IV Prognosis Nested RT-PCRb Quaglino (42)
114 patients stage I–IV and 20 healthy volunteers Survival rate RT-PCR Visus (43)
201 patients stage I–IV and 40 healthy volunteers Overall survival RT-PCR Samija (44)
COX-2 63 human melanocytic skin tumors (17 nevi; 36
primary cutaneous melanomas; 11 lymph-node
metastasis)
Tumor progression IHCc Kuzbicki (45)
101 primary melanomas and 28 metastatic Breslow thickness IHC Becker (46)
cMMP-1 and MMP-3 70 melanomas Disease-free survival IHC Nikkola (47)
MMP-9 71 patients stage IV and 8 healthy volunteers Poor prognosis ELISAd Nikkola (48)
MMP-2 482 melanoma (330 primary and 152 metastatic);
149 nevi (49 normal and 100 dysplastic)
Tumor progression IHC Rotte (49)
VEGF 125 blood samples from patients and 30 healthy
volunteers
Tumor stage; survival ELISA Ugurel (50)
155 melanoma blood samples Tumor progression RT-PCR Quaglino (42)
324 melanoma blood samples Tumor stage ELISA Pelletier (51)
VEGF-C and VEGFR-3 75 melanoma blood samples (stage IV) and 30
healthy volunteers
Tumor burden ELISA Mouawad (52)
Osteopontin 345 melanoma patient blood samples Breslow thickness and survival IHC Rangel (53)
34 invasive growing melanomas Poor prognosis IHC Alonso (54)
106 patient blood samples Tumor stage ELISA Maier (55)
Gal-3 53 benign nevi; 31 dysplastic nevi; 59 in situ
melanoma; 314 primary melanoma; 69 metastatic
melanoma
Tumor progression IHC Brown (56)
YKL-40 110 melanoma patient blood samples (stage IV)
and 245 healthy volunteers
Tumor progression ELISA Schmidt (57)
234 melanoma blood patient samples (stage I–II) Poor prognosis ELISA Schmidt (58)
50 melanoma patient blood (stage I–II) and 61
(stage IV)
Tumor stage ELISA Egberts (41)
MIA 110 with advanced disease and 66 disease free and
65 healthy controls
Survival rate ELISA Diaz-Lagares (59)
125 melanoma patient blood sample Poor prognosis ELISA Essler (60)
CEACAM 49 melanoma patient blood (stage III–IV) Tumor stage; survival ELISA Sivan (61)
S100B 221 melanoma patient blood (stage II–III) Survival rate Line Immunoassay Bouwhuis (62)
20 melanoma patient blood Metastasis detection ELISA Oberholzer (63)
192 melanoma patient blood Poor prognosis ELISA Beyeler (64)
IgG4 33 melanoma patients Progression, overall survival Luminex Karagiannis (65)
IL-8 16 melanoma patients Tumor burden, stage; survival ELISA Sanmamed (66)
aApplies to laboratory assay unless the reference was a meta-analysis.
bReverse-Transcription Polymerase Chain Reaction.
cImmunohistochemistry.
dEnzyme-Linked Immunosorbance Assay.
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disease were found, no correlation with disease progression was
attained (51, 75).
Osteopontin
Osteopontin, a secreted integrin-binding glycol-phosphoprotein,
has been described to reduce apoptosis, enhance tumor growth,
and be a major component for the recruitment of tumor-
promoting stromal cells from the bone marrow (76, 77). In a recent
study, Maier et al. demonstrated that osteopontin in combination
with S100B can help to differentiate patients who are likely to
subsequently relapse and develop metastatic disease from those
who do not (55). Yet, the presence of osteopontin is also associ-
ated with other medical conditions such as autoimmune diseases
and this may translate to false-positive readouts in patients with
melanoma.
YKL-40
YKL-40 is a glycoprotein secreted by many cells including cancer
cells and by immune cells such as macrophages and activated neu-
trophils (78–80). The physiological functions of YKL-40 are yet
not fully understood and reports of its functionality as an inde-
pendent prognostic marker vary (41, 57–59). More importantly,
immunomodulatory drugs such as IL-2 and IFN-α2b stimulate
YKL-40 expression and therefore its use as a biomarker can yield
false-negative readouts during treatment (81).
Melanoma-inhibitory activity protein
The small protein melanoma-inhibitory activity (MIA) is secreted
by melanoma cells and is involved in cell–cell contact by inter-
acting with the extracellular matrix. It is also thought that MIA
promotes tumor cell invasion and metastasis (82). Equally, it was
reported that MIA has a high sensitivity and specificity compared
to other clinically relevant biomarkers such as LDH (59, 69). Ele-
vated levels of MIA correlated with more advanced disease stages,
poorer prognosis, and decreased DFS (59, 69, 77, 83). However,
different studies using multivariate analysis demonstrated higher
rates of false-positive readouts in women, suggesting an alterna-
tive source of MIA may exist and that this protein may participate
in and be influenced by other biological processes unrelated to
malignancy (60, 69, 84).
S100
The family of S100 proteins has been of special interest as diagnos-
tic markers in melanoma over the last decade, since the expression
and secretion of these proteins is much higher in malignant
compared to healthy tissues (85–87). S100 proteins and in par-
ticular S100B were recently found to be elevated in the serum
of melanoma patients with these elevated levels being associated
with poorer prognosis (63, 64), DFS, and OS (88). In a more recent
prognostic study of patients treated with IFN-α2b versus observa-
tion in stage II and III patients, investigators showed that S100B
is associated with worse OS and distant metastasis-free survival
(DMFS). Interestingly, S100B in patients’ sera correlated over time
with disease progression, increasing further in parallel to increases
in disease burden (62). False-positive results can occur after brain,
liver, or renal injury as well as during infectious diseases (89–91).
However, data acquired to date point to the merits of further
evaluation of S100 as a potential clinical tool.
IL-8
Interleukin-8 (IL-8), also known as CXCL8, is a chemokine
produced by malignant cells and associated with inflammatory
responses; it can induce neutrophil chemotaxis and is also thought
to be a potent promoter of angiogenesis. A recent study has
shown that IL-8 correlated with tumor burden, stage, survival, and
response to therapy such as BRAF inhibitors (66). These data show
that IL-8, perhaps in combination with other chemokines and
cytokines that participate in tumor inflammation, has potential as
a prognostic marker and warrants further investigation.
TISSUE-SPECIFIC BIOMARKERS FOR MELANOMA
Tissue specific biomarkers are molecules demonstrated to be
over-represented in cancer lesions, and may facilitate diagno-
sis, early detection, prognosis of disease progression, and patient
stratification.
Cyclooxygenase-2
Cyclooxygenases (COX1–3) are a group of proteins that are impor-
tant modulators in the human body, affecting essential pathways
such as the catabolic metabolism. COX1–3 also converts arachi-
donic acid into prostaglandin. Of this group, COX-2 can be
induced in tumor cells (92, 93). Becker et al. showed a corre-
lation between COX-2 staining intensity and Breslow thickness
in melanoma (46). Furthermore, Kuzbicki et al. reported a higher
COX-2 staining intensity in melanoma lesions compared to benign
nevi (45).
Galectin-3
The Galectin-3 molecule is mainly secreted by inflammatory cells
and is associated with both tumor progression and metastasis
in melanoma (94). However, using a multifactorial Cox regres-
sion analysis, Brown et al. showed an inverse association between
galectin-3 with tumor size (thin tumors had more galectin-3) and
improved OS (56).
Matrix metalloproteinases
Matrix metalloproteinases play an important role in remodel-
ing the tumor tissue microenvironment as they are responsible
for proteolytically breaking components of the local tissue archi-
tecture, promoting tissue remodeling, and facilitating tumor cell
migration (95, 96). For these reasons, the proteins are over-
represented in tumor tissues. Nikkola and colleagues showed
that MMP-1- and MMP-3-positive melanoma metastases corre-
late with decreased DFS (47). Furthermore, Rotte et al. confirmed
a higher expression of MMP-2 in melanoma when compared to
normal and dysplastic nevi. In this study, the levels of MMP-2
expression positively correlated with tumor progression and worse
survival (49). It is, however, noteworthy that this study was con-
ducted using tumor tissue microarrays through the application
of peroxidase developed with 3,3’-diaminobenzidine (DAB – a
brown substrate), making the assessment of MMP-2 difficult to
distinguish from melanoma cells in pigmented lesions.
Cell adhesion molecules
Cancer-associated cell adhesion proteins are proteins that adhere
to different cells, show altered expression levels in cancer, and
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may participate in tumor cell migration, immune cell evasion,
and angiogenesis (97). Molecules such as the carcinoembryonic
antigen-related cell adhesion molecule 1 (CEACAM-1) are known
to foster interactions between somatic cells and immune cells. It
was demonstrated that expression of CEACAM on tumor cells
inhibits immune responses and leads to tumor progression (61).
Investigation of CEACAM-1 expression suggested that it may be
an independent factor to predict the risk of metastasis (98). Stud-
ies have also suggested associations between serum levels of cell
adhesion molecules with the development of metastasis (99–101).
The chondroitin sulfate proteoglycan 4 as a biomarker
The chondroitin sulfate proteoglycan 4 (CSPG4), also known as
the high molecular weight melanoma-associated antigen (HMW-
MAA) or the melanoma-associated chondroitin sulfate proteo-
glycan (MCSP) is a glycoprotein–proteoglycan complex expressed
on the surface of melanoma, glioma, neuroblastoma, certain breast
carcinomas, and acute leukemias (102). CSPG4 is thought to play
crucial roles in cell adhesion, melanoma migration, and metas-
tasis (103). Although CSPG4 is over-expressed in over 80% of
all melanomas, it is found at all disease stages and data so far
have not yielded any correlations with disease progression (104).
However, a recent study reported that a cytoplasmic form of the
protein appears to correspond with response to treatment with
a melanoma vaccine, indicating that CSPG4 may potentially be
evaluated as a marker of response or progression (105).
THE IMMUNE RESPONSE AS A SOURCE OF BIOMARKERS
Cancer development and progression is associated with dysregu-
lated molecular pathways in tumor cells, but it is now accepted that
it may also be affected by cross-talk with the immune response. The
latter could lead either to immune cell activation and destruction
of cancer cells or to immune response redirection and suppres-
sion to support cancer cell survival and metastasis (106). Different
immune sentinels and molecules associated with tumor inflamma-
tion with either possible tumor-promoting or tumor-eradicating
effects may be evaluated as potential biomarkers to predict clin-
ical course or to monitor how patients respond to treatments
(107). For example, the immune checkpoint molecule programed
death-ligand 1 (PD-L1), which is also expressed in melanoma and
other cancers has been described in preliminary studies to identify
enhanced aggressive and invasive disease and to be an indepen-
dent risk factor for worse clinical outcome (108). Furthermore,
gene expression profiling analyses suggest that high expression of
immunological parameters may predict responses to anti-CTLA-4
antibody therapies (109).
The potential value of immune sentinels in cancer could be
exemplified by reports that monitoring tumor infiltrating lympho-
cytes (TIL) (immune score) may be more accurate prognostically
than standard methods such as TNM stage (110, 111). Further
analysis into the phenotype of the TIL revealed that while cyto-
toxic T cells may predict better patient outcomes and responses
to checkpoint blockade therapies, high numbers of regulatory T
cells (Treg: CD4+FoxP3+CD25high) among TIL, or the presence
of myeloid-derived suppressor cells (MDSC) may correlate with
poorer survival in many cancers and with lower clinical response
rates to anti-CTLA-4 antibodies (109, 112–114). Although most
clinical studies are focused on T cells, emerging evidence also
points to a potential prognostic value for B cells in cancer. For
instance, the presence of CD20+ cells among TIL correlated with
a more favorable prognosis in ovarian cancer, while other studies
point to immune regulatory roles for B cells (115). These find-
ings suggest that the specific immune status of patients may be
indicative of capacity to respond to and possibly restrict tumor
progression.
IMMUNOGLOBULINS: ANTIBODY CLASS BIAS AND TUMOR-REACTIVE
RESPONSES
Early disease stages are characterized by mostly minimal disease
burden with no more than 1× 106 tumor cells, which translate
to very low or undetectable serum levels of potential biomarkers.
Unless actively secreted, molecules released from these few cells
may not be easily detectable in the circulation, thus monitoring
such markers could be challenging.
B cells can undergo class switching to produce affinity matured
antibodies in response to tissue damage and to the presence of
antigens, including cancer antigens, and this may happen at early
stages of cancer development. An individual B cell can produce
5,000–20,000 antibodies/min, and B cells can go through mitosis
every 3 days, which can maintain or further enhance antibody pro-
duction (116–118). The potential specificity of B cell and antibody
responses to tumor antigens and amplification of the “tumor sig-
nal”may fulfill all three desirable attributes of a biomarker, namely
detectability, sensitivity, and specificity. In support of this notion,
the immunoglobulin G kappa chain has been shown to be a posi-
tive prognostic biomarker in breast cancer, non-small lung cancer,
and colorectal cancer, not only for monitoring disease progression
but also for predicting the response to neoadjuvant chemotherapy
(115, 119, 120).
Until recently, the nature and functional significance of the
humoral response in cancer were poorly understood. Moreover,
whether and how the humoral response may be “immunoedited”
by tumors has remained unknown. We have reported a tumor-
reactive mature memory B cell compartment in the circulation
of patients with melanoma. By isolating tumor-reactive antibody
clones from patients’ mature B cells, we found that patient-derived
antibodies can activate effector cells to destroy tumor cells ex vivo
by recognizing tumor antigens on the surface of these cells (121).
These findings suggest that host humoral immunity recognizes
the presence of cancer and may potentially be activated. Antibod-
ies, whether administered as therapeutics or expressed by host B
cells, have the potential to induce potent anti-tumoral responses
by sequestering effector cells to destroy tumor cells. However,
since it is known that immunoediting in the tumor microenvi-
ronment may suppress the anti-tumoral functions of T cells, it
would be reasonable to hypothesize that tumor-induced inflam-
matory conditions triggering suppression of T cell functions can
lead to immunoediting of humoral responses as well and may
substantially impair the potency of B cell and antibody functions
against cancer.
Hints that immune escape mechanisms may operate to suppress
tumor-reactive humoral responses came from our findings that
this tumor-reactive memory B cell compartment appears more
prominent at earlier disease stages and is reduced with disease
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progression. It has also been demonstrated that both the broad
and the tumor-reactive mature memory B cell compartments are
reduced in patients with advanced disease (122).
In melanoma, early studies indicated dysregulation and polar-
ization of IgG antibody subclasses in the serum of patients with
melanoma, but the biological relevance and functional implica-
tions of these findings were unclear (123). More recently, the
presence of infiltrating IgG4+ plasma cells in hepatic cholan-
giocarcinomas (124) has been reported, pointing to diverted
immunoglobulin class/subclass distribution in cancer. In sup-
port of these findings, we demonstrated that in melanoma tumor
microenvironments B cells are polarized to favor production of
IgG4, an antibody subclass with substantially restricted effec-
tor functions compared to well-known potent IgG1 antibodies
and with capacity to impair effector functions of tumor-reactive
IgG1 antibodies (65). This bias may occur in “alternative” Th2
cytokine environments in melanoma, where the presence of the
immunoregulatory cytokine IL-10 can favor class switching to
IgG4 and can enhance IgG4 production by class-switched B cells
in the presence of IL-4 (125, 126). This biological relevance of
IgG4 subclass antibodies in disease pathogenesis adds to the rela-
tively newly described roles of IgG4 subclass in some inflammatory
diseases (IgG4-related disease) (127).
Tumor antigen recognition may be another attribute of anti-
bodies that could render them promising potential biomarkers.
This may be facilitated by emerging screening platforms such as
“immunosignaturing,” which is designed to identify reactive anti-
body signatures against panels of antigens, including those found
in cancers. The “signatures” resulting from this process could
allow for the identification of antibody reactivity patterns that
may predict disease course. The potential for this approach has
been demonstrated in the diagnosis of Alzheimer’s disease (128)
and to detect antibodies against brain tumor antigens (129), but it
may also be evaluated as a clinical biomarker tool in other cancers
including melanoma.
Different facets of antibodies, including tumor specificity and
reactivity, as well as antibody class and subclass bias may therefore
be examined in the context of cancer including; as measures of the
potency of adaptive immunity in cancer, as readouts of tumor-
induced immunoediting and as powerful therapeutic agents to
activate patient immune cells against cancer (35). Host humoral
responses associated with tumor-immune escape may be linked to
a higher risk of disease relapse and could point to readily detectable
biomarkers, possibly at early disease stages.
CONCLUDING THOUGHTS
Biomarkers that move beyond the current clinical pathological
and radiological parameters, helping to identify those patients
with early disease at high risk of relapse and guiding therapy
choices for patients with metastatic disease, are still needed. A
number of potential candidate biomarkers, including immuno-
logical markers warrant further evaluation in melanoma. Circu-
lating or tumor-resident immune cells, including those associ-
ated with immunosuppressive forces in melanoma such as Treg
MDSC, IgG4+ B cells, and also cytokines, chemokines, check-
point molecules, and antibodies may point to yet unexplored
biomarker signatures associated with particular clinical outcomes.
Despite the considerable progress made in immune monitoring
technologies, it has been challenging to draw accurate correla-
tions between immunological parameters and clinical outcomes or
patient responses to therapeutic agents. The reasons might include
complex interactions between immune and tumor cells and the
variable patient immune responses, making it difficult to account
for all the interactions required for adequate prognostic readouts.
Even when associations with melanoma are demonstrated, there is
significant variability among patients, possibly reflecting the het-
erogeneity of individual tumors and of individual patient immune
responses.
Other important challenges for biomarker discovery and val-
idation remain. As most biomarkers are normal cellular or
immunological proteins, they can be detected in both healthy and
disease states, reducing their specificity. Additionally, many studies
report relatively small sizes of patient samples, and this may indi-
cate a limitation potentially preventing biomarker selection and
routine use. Future directions may include larger cohorts assessed
in multi-center studies and also assessing combinations of mul-
tiple putative markers to identify specific prognostic footprints.
Finally, complex statistical analyses and comprehensive algorithms
will be needed in order to integrate these multiple lower specificity
biomarkers.
In conclusion, the potential of biomarkers to contribute toward
better clinical monitoring and management will most likely be
aided through further refinement of emerging design, statistical,
bioinformatics, and analytical methods (130), as well as via our
enhanced understanding of disease pathways and tumor-immune
cell cross-talk.
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